Patent ID: 11866449
Assignee: NSC THERAPEUTICS GMBH
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 11:
12. A method of ameliorating Alzheimer's disease in a subject, the method comprising administering to the subject a pharmaceutical composition comprising a crystalline polymorph of (S)-2-ethyl-8-methyl-1-thia-4,8-diazaspiro[4.5]decan-3-one monohydrate, wherein the crystalline polymorph is characterized by an X-ray powder diffraction pattern comprising peaks at 12.3, 17.3, and 17.5° 2θ±0.2° 2θ, and wherein the crystalline polymorph has a water content of 7.2-8%.